Shares of DexCom DXCM moved lower in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 20.87% over the past year to $0.91, which missed the estimate of $0.92.
Revenue of $568,900,000 higher by 22.93% from the same period last year, which beat the estimate of $552,230,000.
Outlook
Dexcom Sees FY21 Sales $2.21B-$2.31B vs $2.33B Est.
How To Listen To The Conference Call
Date: Feb 11, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/8yzhcptu
Technicals
Company's 52-week high was at $456.23
Company's 52-week low was at $182.07
Price action over last quarter: Up 17.50%
Company Overview
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
